Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NuVasive (NUVA), BioDelivery (BDSI) and Amarin (AMRN).
NuVasive (NUVA)
In a report released today, Jason Wittes from Northland Securities maintained a Hold rating on NuVasive, with a price target of $65.00. The company’s shares closed last Tuesday at $53.73.
Wittes has an average return of 18.2% when recommending NuVasive.
According to TipRanks.com, Wittes is ranked #731 out of 6858 analysts.
Currently, the analyst consensus on NuVasive is a Moderate Buy with an average price target of $67.10, which is a 20.4% upside from current levels. In a report issued on July 21, Morgan Stanley also reiterated a Hold rating on the stock.
See today’s analyst top recommended stocks >>
BioDelivery (BDSI)
Northland Securities analyst Tim Chiang maintained a Buy rating on BioDelivery yesterday and set a price target of $9.00. The company’s shares closed last Tuesday at $4.26.
According to TipRanks.com, Chiang is a 2-star analyst with an average return of -0.3% and a 47.5% success rate. Chiang covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Verrica Pharmaceuticals, and Pacira Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioDelivery with a $8.45 average price target.
Amarin (AMRN)
In a report released yesterday, Carl Byrnes from Northland Securities maintained a Buy rating on Amarin, with a price target of $15.00. The company’s shares closed last Tuesday at $7.03, close to its 52-week low of $3.95.
According to TipRanks.com, Byrnes has 0 stars on 0-5 stars ranking scale with an average return of -9.3% and a 35.6% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Opiant Pharmaceuticals, and Aridis Pharmaceuticals.
Currently, the analyst consensus on Amarin is a Moderate Buy with an average price target of $14.17, an 116.3% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMRN:
